IAM
BCTX

Iridian Asset Management’s Briacell Therapeutics BCTX Stock Holding History

Iridian Asset Management’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Hold
65,000
– – 0.07% 40
2026
Q1 		$272K Buy
+65,000
New +$303K 0.11% 41

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
LCM
LuminArx Capital Management New York $224M AUM
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Iridian Asset Management's BCTX Position: Q2 2026 in Review

Iridian Asset Management held its Briacell Therapeutics (BCTX) position steady in Q2 2026 at 65,000 shares worth $211K. The position accounts for 0.07% of the portfolio, ranked #40.

Iridian Asset Management first reported a position in BCTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $272K in Q1 2026. 19 funds tracked by Wall St. Rank hold BCTX as of Q2 2026.

  • Iridian Asset Management held 65,000 shares of Briacell Therapeutics worth $211K as of Q2 2026.
  • Iridian Asset Management left its Briacell Therapeutics share count unchanged in Q2 2026.
  • Briacell Therapeutics made up 0.07% of Iridian Asset Management's portfolio in Q2 2026, its #40 holding.
  • Iridian Asset Management first reported a position in Briacell Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Iridian Asset Management's Briacell Therapeutics position peaked at $272K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2026.

Based on Iridian Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.